ParfumGigi@aol.com

Dear Diana:

There's one about, Mentor an also Inamed. I've, found on the Forbes line. I'll, try to copy it off and send it to, you. Here's the http to one the business wire.

In November, the FDA reversed its 14-year ban on silicone gel-filled breast implants, which cost about twice as much as their saline-filled counterparts, ...

Gigi-Karen ParfumGigi@aol.com

Cosmetic surgery product stocks rose Thursday led by Mentor Corp., which announced late Wednesday that the Food and Drug Administration will allow women who get silicone gel breast implants to choose whether they want to enroll in post-approval studies or not.

Shares of Mentor rose $2.41, or 6.2 percent, to $41.53 after trading at more than three times their average volume. Shares have traded between $37.25 and $54.40 over the past 52 weeks.

Late Wednesday, Mentor said the Food and Drug Administration revised a study design that would have restricted women from getting the company's silicone gel-filled breast implants unless they agreed to participate in follow-up studies.

Surgeons who implant the devices, however, are still bound to participate in the studies and must actively encourage women who choose the implants to participate. Mentor said that it has already enrolled about 4,000 women into the study, and gained approval for about 2,600 participating doctors.

In November, the FDA reversed its 14-year ban on silicone gel-filled breast implants, which cost about twice as much as their saline-filled counterparts, but look and feel more real. The FDA took gel-filled implants off the market in 1992 after thousands of women claimed the implants were responsible for health problems.

Shares of Mentor's competitor, Allergan Inc. (nyse: AGN - news - people ), also rose. Allergan shares grew by $3.50, or 3 percent, to $121.34 on above-average volume.

Approvals for Mentor's and Allergan's implants required that the companies complete 10-year studies on women who have already received the implants to study leaks, as well as new decade-long studies of the safety of the devices in 40,000 women.

Allergan spokeswoman Crystal Cienfuegos said that Allergan's post-marketing program has always been voluntary, and that patients are given a $10 cash incentives to fill out questionnaires and $100 credits from plastic surgeons to follow-up with exams after one, four, and 10 years after implantation.

While not in the breast implant sector, Allergan's competitor in the wrinkle correction sector, Medicis Pharmaceutical Corp. (nyse: MRX - news - people ), also saw their shares climb Thursday.

Shares of Medicis rose 83 cents, or 2.8 percent, to $30.93 on nearly triple their average volume.